SCHEMBL20239227

SCHEMBL20239227

CNS(=O)(=O)Cc1ccc(Oc2cc(CNc3ncc(Cl)cn3)nc(OC)n2)cc1

nearest known ligand 0.56

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
DGAT2 Q96PD7 1/20 0.56
KDM4E B2RXH2 1/20 0.38
VNN1 O95497 4/20 0.37
CYP2C9 P11712 1/20 0.35
P2RX3 P56373 2/20 0.34
CA1 P00915 1/20 0.34
CA2 P00918 1/20 0.34
CA9 Q16790 1/20 0.34
CYP17A1 P05093 1/20 0.34
CLK1 P49759 2/20 0.33
CLK2 P49760 2/20 0.33
DYRK1A Q13627 2/20 0.33
CLK4 Q9HAZ1 2/20 0.33
DYRK1B Q9Y463 2/20 0.33
SMN1; SMN2 Q16637 1/20 0.32
CYP3A4 P08684 1/20 0.32
TP53 P04637 2/20 0.32
LMNA P02545 1/20 0.32
MAPT P10636 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL16738674 0.89 DGAT2 (0.57) DGAT2KDM4EVNN1CYP2C9CYP17A1
SCHEMBL20239333 0.88 DGAT2 (0.56) DGAT2KDM4EVNN1CYP2C9P2RX3
SCHEMBL20239203 0.88 DGAT2 (0.59) DGAT2KDM4EVNN1CYP2C9SMN1; SMN2
SCHEMBL20239171 0.87 DGAT2 (0.56) DGAT2KDM4EVNN1CYP2C9CYP17A1
SCHEMBL20239176 0.86 DGAT2 (0.55) DGAT2KDM4EVNN1CYP2C9CA1
SCHEMBL18249759 0.85 DGAT2 (0.49) DGAT2KDM4EVNN1CYP2C9CYP17A1
SCHEMBL20239169 0.85 DGAT2 (0.54) DGAT2KDM4EVNN1CYP2C9SMN1; SMN2
SCHEMBL18249757 0.85 DGAT2 (0.54) DGAT2KDM4EVNN1P2RX3SMN1; SMN2
SCHEMBL20239272 0.84 DGAT2 (0.55) DGAT2KDM4EVNN1CYP2C9SMN1; SMN2
SCHEMBL20239252 0.81 SMN1; SMN2 (0.45) DGAT2KDM4ESMN1; SMN2CYP3A4LMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10053429-B2 DGAT2 inhibitors ELI LILLY AND COMPANY (US) 2018-08-21 US disclosed
US-20180162825-A1 NOVEL DGAT2 INHIBITORS ELI LILY AND COMPANY (US) 2018-06-14 US disclosed
US-20180162825-A1 NOVEL DGAT2 INHIBITORS ELI LILY AND COMPANY (US) 2018-06-14 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20180162825-A1 NOVEL DGAT2 INHIBITORS DGAT2, DGAT1, LCAT DGAT2 1/4885KDM4E 4070/4885VNN1 3148/4885
US-10053429-B2 DGAT2 inhibitors DGAT2, DGAT1, LCAT DGAT2 1/4885KDM4E 3891/4885VNN1 3615/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.